| Bax inhibitor peptide V5Bax inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.19%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- MS (Retest)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Cell experiment [1,2]: | |
Cell lines | Mouse islet isolation |
Preparation method | The solubility of this compound in DMSO is >24.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0-100 μM, 24 h |
Applications | Bax inhibitor peptide V5 (0-50 μM) reduced cell death in STF-cMyc cells but not in SW620 or NCI-H23 cells. BIP V5 does not result in any significant effect on cell cycle arrest at the G2/M phase. In mouse islet isolation, BIP V5 (100 μM) treatment upregulated expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulated expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively. |
| Animal experiment [2]: | |
Animal models | Streptozotocin-induced diabetic mice |
Dosage form | 100 μmol/l |
Application | Following transplantation in streptozotocin-induced diabetic mice, 150 BIP V5-treated islet equivalents functioned as well as 450 control untreated islet equivalents in normalizing blood glucose. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Jo M J, Paek A R, Choi J S, et al. Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment[J]. European journal of pharmacology, 2015, 769: 257-265. [2]. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol, 2003, 5(4): 352-357. [2].Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, et al. Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes, 2007, 56(5): 1259-1267. | |
Bax inhibitor peptide V5 Dilution Calculator
calculate
Bax inhibitor peptide V5 Molarity Calculator
calculate
| Cas No. | 579492-81-2 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | (S)-6-amino-2-((Z)-((S)-2-((Z)-((S)-2-((Z)-(((S)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-yl)(hydroxy)methylene)amino)-1-hydroxy-4-(methylthio)butylidene)amino)-1-hydroxy-4-methylpentylidene)amino)hexanoic acid | ||
| Canonical SMILES | CC(C[C@@](/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](N)([H])C(C)C)=O)([H])CCSC)([H])/C(O)=N/[C@@](C(O)=O)([H])CCCCN)C | ||
| Formula | C27H50N6O6S | M.Wt | 586.79 |
| Solubility | ≥29.35mg/mL in DMSO | Storage | Desiccate at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Bax inhibitor peptide V5 (BIP V5) is a peptide inhibitor of Bax translocation to mitochondria [1].
Bax is a pro-apoptotic member of Bcl-2 family proteins and plays an important role in mitochondria-dependent apoptosis. Bax stays in the cytosol and transfers into mitochondria after apoptotic stimuli [1].
BIP V5 is a membrane-permeable peptide inhibitor of Bax translocation to mitochondria. In HeLa cells, BIP V5 protected cells from UVC- and STS-induced apoptosis. In U87-MG glioma cells, MCF-7 breast cancer cells and LNCaP prostate cancer cells, BIP V5 also inhibited apoptosis induced by anti-cancer drugs cisplatin, etoposide and doxorubicin. While BIP V5 did not suppress UVC- or STS-induced apoptosis in Bax-deficient cells (DU145), which suggested BIP V5 only suppressed Bax-mediated apoptosis. Also, BIP (V5) inhibited Bax translocation to mitochondria stimulated by UVC irradiation and STS treatment. The caspase activation and the release of cytochrome c from mitochondria triggered by apoptotic stimuli were also significantly inhibited by BIP V5. BIP V5 inhibited the interaction of Ku70 and endogenous Bax in a dose-dependent way [1].
In a mouse model, BIP V5 increased expression of anti-apoptotic proteins XIAP and Bcl-2 by more than 11- and 3-fold and reduced expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κ B-p65 by 10, 30, and nearly 50%, respectively. Also, BIP V5 increased glucose-responsive insulin secretion [2].
References:[1]. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol, 2003, 5(4): 352-357.[2]. Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, et al. Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes, 2007, 56(5): 1259-1267.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
我用conA和LPS分别刺激脾细胞，当然细胞均有明显的增殖，可是如果把这两种有丝分裂原同时用来刺激细胞时，细胞的增殖明显受到了抑制，比起单独采用ConA或者LPS都低很多。conA和LPS分别刺激T细胞和B细胞的增殖，两者同时加入时，作用应该更强，为什么反而大幅减弱呢？
此外，我研究的这种成分单独刺激皮细胞时，细胞也有一定程度的增殖，但是如果这种物质与conA联合使用时，比起单独用conA时，细胞的增殖程度明显降低了一些，这又是什么原因呢？难道可以解释为我研究的这种物质有类似于LPS的作用——刺激B细胞增殖？
如果真的是这样来解释，哪位大侠能把第一个现象（conA和LPS共同作用产生拮抗）的机理帮我解释一下呢？
当抗体结合到示踪剂上时，340nm的激发光激发铕标分子，导致能量转移到Alexa Fluor 647染料上，结果产生665nm的发射光。荧光的强度与样品中的cAMP含量成反比。
本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体，激动剂刺激导致665nm的荧光强度降低，而拮抗剂则可以逆转这一效应；对于偶联Gαi的受体，在激动剂刺激的同时用forskolin刺激cAMP产生，那么激动剂则抑制forskolin诱导的cAMP的生成，因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。
该试剂盒的灵敏度很高，室温下反应在20h内是稳定的。本试剂盒适用于在384孔板中进行24μl的微量分析。
2.保存条件
避光2~4℃保存，过期时间见装。
3.盒内试剂
cAMP标准品：1管，1ml。（50μM）
生物素标记的cAMP（b-cAMP）：1管，25μl。
铕标的抗生物素蛋白链菌素：1管，25μl。
荧光标记的cAMP抗体：1管，40μl。
检测缓冲液：1瓶，25ml。
4.需要自配的其他溶液
l Hank’s balanced salt solution (HBSS): NaCl 8.0g、CaCl2 0.14g、KCl 0.4g、 KH2PO4 0.06g、Na2HPO4?7H2O0.09g、MgCl2.6H2O0.10 g、MgSO4.7H2O0.10 g、NaHCO30.35g、葡萄糖1.0g，加H2O至 1000ml (用7.5%NaHCO调节PH值=7.4)
l Versene消化液（1L）：EDTA 0.372 g，NaCl 8.0g，KCl 0.20 g，KH2PO40.20g，Na2HPO4 1.15 g，D-glucouse 0.2 g，pH 7.4
l HEPES缓冲液(1mol/L)：取2.383gHEPES溶于10ml去离子水中。
l 7.5%BSA溶液：取0.75gBSA溶于10ml去离子水中
l 0.5M IBMX溶液：11.11mg IBMX溶于100μl DMSO中，-20℃冻存。
l 刺激缓冲液（SB）：14 ml HBSS(1×)+75μlHEPES(1mol/L)+200μlBSA (7.5%)。(注：在测定细胞cAMP时，反应缓冲液中要加入IBMX 0.5mmol/L)
l 吗啡贮存液(10mM)：盐酸吗啡37.585mg溶于10ml生理盐水中，0.22μm滤膜过滤除菌，4℃保存备用。
l 纳络酮母液(100mM)：纳络酮4mg溶于100μl 生理盐水中，用时工作液按照1:500稀释，溶剂为含有IBMX的反应缓冲液。
抑制剂刺激细胞后，需要用PBS清洗后再做后续实验吗
我做的是细胞因子的刺激和抑制某条通路后观察是否有影响，分组为空白组，空白+抑制剂，刺激组，刺激+抑制剂，最开始用的单因素方差分析，LSD-T和SNK-Q检验，但是同学说我这里面有两个处理因素，所以不能单因素方差分析，应该直接空白和空白+抑制，空白和刺激，刺激和刺激+抑制剂进行独立样本T检验，现在脑子是混乱的，拜托园子里的大神们帮我看看，感激不尽！！
